<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895036</url>
  </required_header>
  <id_info>
    <org_study_id>6332</org_study_id>
    <nct_id>NCT01895036</nct_id>
  </id_info>
  <brief_title>Nalrexone Facilitated Discontinuation of Buprenorphine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of buprenorphine as a long-term agonist treatment has been offset by the
      emergence of intolerable withdrawal phenomena in a subset of individuals on chronic
      maintenance who attempt to discontinue the medication. Efforts are needed to better
      understand these challenges encountered with buprenorphine, as well as to develop
      interventions to facilitate medication discontinuation.

      Emerging evidence suggests that these difficulties may be related to the unique effects of
      buprenorphine on sites other than mu-opioid receptors, such as kappa-opioid receptors.
      Kappa-opioid agonism produces aversive, dysphoric-like effects, and can also increase the
      likelihood of reinstatement to drug use through stress-mediated mechanisms. Some of the
      discomfort observed during drug taper may therefore be due to the attenuation or loss of
      kappa-opioid antagonism afforded by buprenorphine, as well as to rebound kappa-opioid
      activation. Naltrexone represents a promising candidate for extending kappa blockade and
      therefore for facilitating discontinuation attempts. Naltrexone and its active metabolite
      6-Beta-naltrexol are competitive antagonists at the mu and kappa receptors, and to a lesser
      extent at the delta receptor. Naltrexone and buprenorphine have comparable affinity for the
      mu-opioid receptor and thus buprenorphine is displaced by naltrexone more gradually than are
      other opioids with less affinity; a careful titration of naltrexone is less likely,
      therefore, to precipitate severe withdrawal states in individuals coming off buprenorphine,
      and the two have been combined to good effect in other settings.

      The purpose of this study is therefore to investigate the feasibility of naltrexone
      augmentation on discontinuing buprenorphine in eligible patients on long-term maintenance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Discontinuation of Buprenorphine</measure>
    <time_frame>7 weeks</time_frame>
    <description>Number of individuals successfully discontinuing buprenorphine during the inpatient phase and through follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Stable Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, aged 18-49.

          2. Currently maintained on buprenorphine, with a clinically acceptable interest in
             tapering or discontinuing it

          3. Willingness to switch over to naltrexone

          4. In otherwise good health based on complete medical history, physical examination,
             vital signs measurement, ECG, and laboratory tests (hematology, blood chemistry,
             urinalysis) within normal ranges.

          5. Able to give informed consent and comply with study procedures,

          6. Currently on 2 mg or less of buprenorphine.

          7. Voluntarily seeking treatment for opioid dependence.

        Exclusion Criteria:

          1. Significant current suicidal risk or 1 or more suicide attempts within the past year

          2. History of accidental drug overdose in the last three years defined as an episode of
             opioid-induced unconsciousness or incapacitation, whether or not medical treatment was
             sought or received.

          3. Positive serum pregnancy test, lactation, or unwillingness to use a satisfactory
             method of birth control

          4. Active psychiatric disorder which might interfere with participation or make
             participation hazardous, including DSM-IV organic mental disorder, psychotic disorder,
             or bipolar disorder with mania

          5. History of allergic reaction, adverse reaction, or sensitivity to any study
             medication.

          6. Acute hepatitis with SGOT or SGPT &gt; 3 times the upper end of the laboratory normal
             range (chronic hepatitis is acceptable as we have found naltrexone treatment well
             tolerate and safe among patients with chronic hepatitis)

          7. Currently prescribed or regularly taking opioids for chronic pain

          8. Current participation in another intensive psychotherapy or substance abuse treatment
             program, or participation in another treatment study.

          9. Opioid dependence is not well-managed, and characterized by relapses, slips, or missed
             doses

         10. Concurrent treatment with psychotropic medications which may interact adversely with
             naltrexone, such as duloxetine and valproic acid.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NYSPI</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>August 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maintained on 2 mg or less of buprenorphine, in which discontinuation of agonist treatment is clinically feasible but difficult</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone</title>
          <description>PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
Naltrexone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone</title>
          <description>PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
Naltrexone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Discontinuation of Buprenorphine</title>
        <description>Number of individuals successfully discontinuing buprenorphine during the inpatient phase and through follow-up.</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
Naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Discontinuation of Buprenorphine</title>
          <description>Number of individuals successfully discontinuing buprenorphine during the inpatient phase and through follow-up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning with entry into the protocol and through 1 month after study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
          <description>PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
Naltrexone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Sherman</name_or_title>
      <organization>NYSPI</organization>
      <phone>6467747158</phone>
      <email>lsherma@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

